invivodata Granted Patent on Patient Compliance System
Key Functionality Drives Data Precision in Patient-Reported Outcomes-Based Research
PITTSBURGH -- June 21, 2005 -- invivodata inc., the industry leader in electronic patient-reported outcomes (ePRO) solutions for global clinical research, today announced that the U.S. Patent and Trademark Office has issued patent No. 6,879,970 to the company. This patent covers management of subject compliance in clinical research.
"We are very pleased to be issued this patent," said Saul Shiffman, Ph.D., co-founder and chief science officer at invivodata and one of the inventors of this intellectual property. "We first began using electronic diaries (eDiaries) in our research in 1987 as an outgrowth of our behavioral science research. By applying our unique scientific methods and software algorithms, we have been able to identify ways to deliver unmatched patient compliance in clinical research."
Patient compliance plays a critical role in the success of clinical trials. By using DiaryPRO, invivodata's electronic patient diary, which is based on these patented compliance-enhancing methods, clinical trial sponsors can capture important PRO data from patients at the point of their experience. This approach to capturing real-time data has been proved to significantly improve trial sensitivity, yielding a more accurate measurement of treatment effect.
invivodata intends to work closely and professionally with other suppliers that may desire to include this innovative functionality in their products. Initial contacts have already been made with the key eDiary providers. "We will initiate and support an open dialogue with other eDiary providers that may want to include patient compliance features in their solutions," said Doug Engfer, president and CEO of invivodata. "This constructive dialogue is essential to ensure that the drug-development community has access to the best possible research tools, while protecting our innovative and valuable intellectual property."
About invivodata inc.
invivodata (
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025